Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Bms-182874. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 7/20 | 0.98 |
| ▸ | EDNRB | P24530 | 3/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-182874 SCHEMBL802730 | 0.99 | EDNRA (1.00) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7949156 | 0.88 | EDNRA (0.81) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7857311 | 0.87 | EDNRA (1.00) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL6767574 | 0.86 | EDNRA (0.77) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7860473 | 0.86 | EDNRA (0.77) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7949496 | 0.85 | EDNRA (0.76) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL8784615 | 0.85 | EDNRA (0.76) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7939545 | 0.84 | EDNRA (0.74) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7951138 | 0.84 | EDNRA (0.74) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7946125 | 0.84 | EDNRA (1.00) | EDNRAEDNRBKDM4EMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828368-B2 | Therapeutic treatments using centhaquin | MIDWESTERN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| EP-2424530-B1 | METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS | UNIV MIDWESTERN (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERSITY (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120070513-A1 | Method and Composition for Treating Diabetic Ketoacidosis | GULATI ANIL (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2424529-A2 | NOVEL THERAPEUTIC TREATMENTS USING CENTHAQUIN | Midwestern University (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2424530-A2 | METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS | Midwestern University (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010127096-A2 | NOVEL THERAPEUTIC TREATMENTS USING CENTHAQUIN | MIDWESTERN UNIVERSITY (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127197-A2 | METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS | MIDWESTERN UNIVERSITY (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRA 141/4885EDNRB 148/4885KDM4E 3799/4885 |
| US-10828368-B2 | Therapeutic treatments using centhaquin | ADRA2A, ADRB3, HSPH1 | EDNRA 429/4885EDNRB 502/4885KDM4E 4229/4885 |
| US-20120070513-A1 | Method and Composition for Treating Diabetic Ketoacidosis | EDNRB, EGLN3, BDKRB2 | EDNRA 4/4885EDNRB 1/4885KDM4E 1518/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRA 141/4885EDNRB 148/4885KDM4E 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.